Educational guide for research and informational purposes only. Not medical advice.
SLU-PP-332 is a first-in-class synthetic agonist for the estrogen-related receptor alpha (ERRα), a nuclear receptor that functions as a master regulator of mitochondrial biogenesis and oxidative metabolism. It belongs to the emerging category of "exercise mimetics" — compounds that activate the molecular signaling pathways induced by aerobic exercise at the cellular level, without requiring physical exertion to trigger them.
This does not mean SLU-PP-332 replaces exercise. What it means is that it activates specific metabolic programs — particularly the ones responsible for fat oxidation capacity, mitochondrial density, and endurance adaptation — that typically require sustained aerobic training to upregulate. The implications for athletic performance, body composition, and metabolic disease are significant.
The ERRα Receptor — What It Controls
Estrogen-related receptors are orphan nuclear receptors — meaning they were identified structurally before their endogenous ligand was known. ERRα, ERRβ, and ERRγ all share structural homology with estrogen receptors but bind different compounds and regulate different genes.
ERRα specifically controls a gene network responsible for:
- Mitochondrial biogenesis — production of new mitochondria, increasing the cell's capacity to perform aerobic metabolism
- Fatty acid oxidation (FAO) — the enzymes responsible for importing and burning long-chain fatty acids (HADHA, HADHB, ACADL, ACADM)
- Oxidative phosphorylation — the electron transport chain complexes that convert NADH and FADH2 into ATP
- TCA cycle enzymes — the Krebs cycle machinery that feeds electrons into oxidative phosphorylation
- PGC-1α interaction — ERRα is a direct transcriptional target of PGC-1α, the "master regulator of mitochondrial biogenesis" that is induced by exercise and cold exposure
When ERRα is activated, it effectively tells the cell: produce more mitochondria and upregulate fat-burning capacity. This is exactly the molecular signature of aerobic exercise adaptation.
What SLU-PP-332 Does Specifically
SLU-PP-332 was developed at Washington University (St. Louis — hence the "SLU" designation) as a potent, selective ERRα agonist. Earlier research compounds (like GSK4716) had some ERRα activity but lacked selectivity and potency. SLU-PP-332 represents a significant improvement in compound optimization.
Preclinical Research Findings
The landmark 2023 study by Zhu et al. (published in the Journal of the American Chemical Society) showed:
- SLU-PP-332 administration in sedentary mice produced a gene expression profile in skeletal muscle that closely matched endurance-trained mice
- Treated mice showed 50% improvement in running endurance compared to controls — without additional exercise training
- Significant upregulation of oxidative muscle fiber gene expression (myosin heavy chain isoforms associated with slow-twitch, fatigue-resistant fibers)
- Increased expression of fatty acid oxidation enzymes: HADHA, ACADL, ACADM
- Enhanced mitochondrial density in skeletal muscle by electron microscopy
Metabolic Effects
- Increased resting fat oxidation — more fat burned at baseline metabolic rate, even without increased activity
- Improved insulin sensitivity — mitochondrial dysfunction is directly linked to insulin resistance; ERRα activation improves glucose disposal
- Reduced respiratory exchange ratio (RER) — a shift toward fat as primary fuel substrate, confirmed by metabolic chamber data in animal studies
- Heart protection in heart failure models — ERRα is highly expressed in cardiac tissue; SLU-PP-332 improved cardiac function in failing heart models by restoring mitochondrial metabolism
SLU-PP-332 vs. Other Exercise Mimetics
| Compound | Primary Target | Key Effect | Evidence Base |
|---|---|---|---|
| SLU-PP-332 | ERRα (nuclear receptor) | Mitochondrial biogenesis, FAO, endurance | Preclinical (2023, strong) |
| GW501516 (Cardarine) | PPARδ | Fat oxidation, endurance | Preclinical; abandoned due to carcinogenicity signals |
| AICAR | AMPK (indirect) | Glucose uptake, mitochondrial biogenesis | Preclinical; poor bioavailability |
| MOTS-C | AMPK (mitochondrial-derived) | AMPK activation, insulin sensitivity | Preclinical + early human |
| Metformin | Complex I / AMPK | Glucose lowering, mild AMPK activation | Extensive human data (but blunts training adaptation) |
The critical distinction between SLU-PP-332 and GW501516 (Cardarine) — which is sometimes referenced in similar contexts — is the safety profile. GW501516 was abandoned in Phase II trials due to dose-dependent cancer signals in multiple tissue types. SLU-PP-332's ERRα selectivity and mechanism do not carry the same PPARδ-mediated proliferative concerns seen with GW501516, though long-term human safety data is not yet available.
Who Is SLU-PP-332 Most Relevant For?
Athletes and High Performers
For already-trained individuals, SLU-PP-332 may push mitochondrial adaptation beyond what training alone produces — analogous to altitude training creating a higher density of mitochondrial enzymes before a competition. The endurance and fat oxidation improvements could translate directly to sustained power output and reduced glycogen dependence.
Metabolic Dysfunction
Individuals with insulin resistance, type 2 diabetes, or metabolic syndrome have impaired mitochondrial function as a core feature of the condition. ERRα activation directly addresses this at the gene regulatory level — not by compensating downstream (like metformin or insulin), but by restoring the upstream capacity for aerobic metabolism.
Fat Loss Without GLP-1
For those who cannot or choose not to use GLP-1 therapy, SLU-PP-332 increases the body's capacity to oxidize fat — particularly when combined with compounds that increase fat mobilization (tesamorelin, MOTS-C) and cofactor support (NAD+). This creates a fat loss effect without appetite suppression.
Stack Integration
The Metabolic Optimizer Stack
SLU-PP-332 is a core component of the metabolic optimizer approach — working from the nuclear receptor level while partner compounds address mitochondrial function (MOTS-C), cofactor availability (NAD+), and GH-mediated lipolysis (tesamorelin):
- SLU-PP-332 5mg — ERRα agonism, mitochondrial biogenesis
- MOTS-C 10mg — AMPK activation, insulin sensitivity
- NAD+ 500mg — mitochondrial cofactor for electron transport
- Tesamorelin 5mg — GH-mediated lipolysis, visceral fat mobilization
The Athletic Performance Stack
SLU-PP-332 + BPC-157 + CJC-1295/Ipamorelin addresses endurance, recovery, and GH axis support simultaneously — the combination relevant for athletes who want performance adaptation without PED risk.
Current Research Status and Limitations
SLU-PP-332 is in early-stage preclinical research. The 2023 Zhu et al. data is compelling but represents rodent studies. Human pharmacokinetics, optimal dosing, long-term safety, and full tissue distribution have not been established in clinical trials.
What is known:
- ERRα activation is well-characterized in human cell lines and consistent with rodent findings
- ERRα is a validated target — its role in human mitochondrial disease (loss-of-function mutations cause cardiomyopathy) confirms biological relevance
- Mechanism is distinct from PPARδ agonists (GW501516) and does not carry the same proliferative signals in preliminary evaluation
What is not yet known:
- Human dosing — rodent doses do not translate linearly
- Long-term effects on cardiac ERRα signaling (ERRα is highly expressed in heart; sustained agonism effects unknown)
- Interaction with existing medications (warfarin, statins, thyroid hormone) at CYP enzyme level
References
- Zhu W, et al. Pharmacological Activation of ERRα Mimics Endurance Exercise and Reprograms Skeletal Muscle Gene Expression. J Am Chem Soc. 2023;145(14):7843–7853.
- Dufour CR, et al. Genome-Wide Orchestration of Cardiac Functions by ERRα. Cell Metab. 2007;5(5):345–356.
- Huss JM, et al. ERRα Drives the Assembly of Mitochondrial Supercomplexes and Controls Oxidative Capacity. Mol Cell Biol. 2011;31(18):3764–3776.
- Audet-Walsh É, Giguère V. The Multiple Universes of Estrogen-Related Receptor α and γ in Metabolic Control. J Steroid Biochem Mol Biol. 2015;153:25–32.
- Narkar VA, et al. AMPK and PPARδ Agonists Are Exercise Mimetics. Cell. 2008;134(3):405–415.
Educational Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before initiating any peptide protocol.
FitAF Performance — Educational content only.
